0.74%
1.12%
-7.51%
20.80%
49.50%
-40.95%
-48.10%
AI Spotlight on VIMIAN
Company Description
Vimian Group AB (publ) engages in the animal health business worldwide.It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments.The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name.The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Market Data
| Last Price | 40.65 |
| Change Percentage | 0.74% |
| Open | 40.35 |
| Previous Close | 40.35 |
| Market Cap ( Millions) | 21017 |
| Volume | 134479 |
| Year High | 47.2 |
| Year Low | 25.18 |
| M A 50 | 40.77 |
| M A 200 | 38.95 |
Financial Ratios
| FCF Yield | 1.96% |
| Dividend Yield | 0.00% |
| ROE | 0.04% |
| Debt / Equity | 37.66% |
| Net Debt / EBIDTA | 298.01% |
| Price To Book | 2.77 |
| Price Earnings Ratio | 7210.1 |
| Price To FCF | 51.12 |
| Price To sales | 5.18 |
| EV / EBITDA | 28.63 |
News
- Jan -16 - Insider Favorites For Growth In January 2025
- Jan -08 - Vimian Group Among 3 Stocks Estimated To Be Trading Below Their Intrinsic Value
- Dec -18 - 3 Growth Companies With Insider Ownership Up To 18%
- Nov -28 - November 2024's Estimated Undervalued Stock Opportunities
- Nov -13 - Top Growth Companies With Insider Ownership November 2024
- Oct -30 - 3 Stocks Estimated To Be Up To 39% Below Their Intrinsic Value
- Oct -14 - 3 Swedish Stocks Estimated To Be Up To 48.8% Below Intrinsic Value
- Oct -09 - Swedish Growth Companies With High Insider Ownership October 2024
- Sep -27 - 3 Swedish Stocks That May Be Undervalued In September 2024
- Sep -10 - Top 3 Swedish Growth Stocks With High Insider Ownership In September 2024
- Sep -06 - 3 Swedish Growth Stocks With Up To 35% Insider Ownership
- Sep -06 - 3 Swedish Growth Stocks With High Insider Ownership
- Sep -05 - Top 3 Swedish Growth Stocks With High Insider Ownership In September 2024
- Sep -05 - CellaVision And 2 Other Swedish Stocks Estimated To Be Trading Below Fair Value
- Sep -05 - 3 Swedish Growth Companies With High Insider Ownership
- Sep -02 - Top Swedish Growth Stocks With High Insider Ownership In September 2024
- Aug -21 - 3 Swedish Insider-Owned Growth Stocks With Up To 22% Revenue Growth
- Aug -21 - Top Swedish Growth Stocks With High Insider Ownership August 2024
- Aug -20 - Discover 3 Swedish Stocks That Might Be Undervalued
- Aug -19 - Top Swedish Growth Companies With High Insider Ownership August 2024
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Specialty Pharma
Expected Growth : 9 %
What the company do ?
Specialty Pharma from Vimian Group AB (publ) focuses on developing and commercializing niche pharmaceutical products for specific therapeutic areas, improving patient outcomes.
Why we expect these perspectives ?
Vimian Group AB's Specialty Pharma segment growth of 9% is driven by increasing demand for niche and orphan drugs, strategic M&A, and expansion into new markets. Additionally, investments in R&D and regulatory approvals for new products have contributed to the segment's growth.
Segment n°2 -> MedTech
Expected Growth : 7 %
What the company do ?
MedTech from Vimian Group AB (publ) is a leading veterinary healthcare technology company providing innovative solutions for veterinary clinics and hospitals.
Why we expect these perspectives ?
Vimian Group AB's MedTech segment growth of 7% is driven by increasing demand for pet healthcare, advancements in veterinary diagnostic technologies, and strategic acquisitions. The growing pet humanization trend, rising veterinary care expenditure, and expansion into new markets also contribute to the segment's growth.
Segment n°3 -> Veterinary
Expected Growth : 10 %
What the company do ?
Veterinary from Vimian Group AB (publ) provides veterinary care services, including diagnostics, and sells veterinary products, serving animal health professionals and pet owners.
Why we expect these perspectives ?
Vimian Group AB's 10% growth in Veterinary segment is driven by increasing pet humanization, rising demand for premium pet care, and growing adoption of digital veterinary services. Additionally, strategic acquisitions, expansion into new markets, and investments in research and development are contributing to the segment's growth.
Segment n°4 -> Diagnostics
Expected Growth : 8 %
What the company do ?
Diagnostics from Vimian Group AB (publ) refers to the company's medical imaging and diagnostics segment, providing imaging and diagnostic solutions for healthcare professionals.
Why we expect these perspectives ?
Vimian Group AB's diagnostics segment growth is driven by increasing pet humanization, rising demand for preventive care, and advancements in veterinary diagnostic technologies. The company's strategic acquisitions, expanded product offerings, and growing presence in emerging markets also contribute to its 8% growth rate.
Vimian Group Ab (Publ) Products
| Product Range | What is it ? |
|---|---|
| Veterinary Diagnostic Services | Vimian Group AB provides veterinary diagnostic services, including laboratory testing, imaging, and pathology services to help veterinarians diagnose and treat animals. |
| Veterinary Consulting Services | Vimian Group AB offers veterinary consulting services, providing expert advice and guidance to veterinarians, pet owners, and animal health companies. |
| Animal Health Products | Vimian Group AB develops and distributes animal health products, including pharmaceuticals, vaccines, and nutritional supplements. |
| Data Analytics and Insights | Vimian Group AB provides data analytics and insights to help veterinarians, pet owners, and animal health companies make informed decisions. |
| Digital Health Platforms | Vimian Group AB develops and operates digital health platforms, including telemedicine and online consultation services. |
Vimian Group AB (publ)'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Vimian Group AB (publ) is moderate due to the presence of alternative products and services in the animal health industry.
Bargaining Power Of Customers
The bargaining power of customers is low for Vimian Group AB (publ) as the company has a diverse customer base and is not heavily dependent on a single customer.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate for Vimian Group AB (publ) as the company relies on a few key suppliers for raw materials and services.
Threat Of New Entrants
The threat of new entrants is low for Vimian Group AB (publ) due to the high barriers to entry in the animal health industry, including regulatory hurdles and significant capital requirements.
Intensity Of Rivalry
The intensity of rivalry is high in the animal health industry, with several established players competing for market share, including Vimian Group AB (publ).
Capital Structure
| Value | |
|---|---|
| Debt Weight | 37.35% |
| Debt Cost | 11.38% |
| Equity Weight | 62.65% |
| Equity Cost | 11.50% |
| WACC | 11.45% |
| Leverage | 59.62% |
Vimian Group AB (publ) : Quality Control
Vimian Group AB (publ) passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| MYNZ | Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer … |
| CNTG | Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It … |
| CBAV.MC | Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics … |
| SLV.WA | Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. … |
| LBIRD.PA | Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two divisions, Photonics and Medical. The Photonics division offers solid-state lasers, … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Clínica Baviera
A-Score
1-Year Total Return ->
🥈
Mainz Biomed
A-Score
1-Year Total Return ->
🥉
Selvita
A-Score
1-Year Total Return ->
4
Centogene
A-Score
1-Year Total Return ->
5
Vimian Group
A-Score
1-Year Total Return ->
6
